Molecular biologic and Epstein-Barr virologic advances in extranodal natural killer/T cell lymphoma over the past four decades
Decades of research show localized rare lymphomas now achieve >80% survival with modern treatment, and new immunotherapy combinations offer hope for advanced cases.
This 40-year synthesis of ENKTL molecular biology describes how EBV LMP1 orchestrates oncogenic signaling, reviews evolving diagnostic and therapeutic milestones including MDR-independent chemoradiotherapy achieving >80% OS in localized disease, and outlines emerging immunotherapy and targeted therapy directions. Particularly notable is the identification of soluble CD27 as a novel biomarker and the shift toward checkpoint inhibitor combination regimens for advanced/relapsed disease.
What the study was
- Study design
- Narrative review (~40 years of literature)
- Population
- Patients with extranodal NK/T-cell lymphoma (ENKTL), predominantly East Asian
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Auris Nasus Larynx
Why it surfaced
Comprehensive expert review by a leading ENKTL researcher; useful for pipeline context on a rare hematologic malignancy with East Asian predilection; no new data, review only.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.